These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 22234519

  • 1. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y.
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [Abstract] [Full Text] [Related]

  • 2. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
    Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, Takatsuka Y, Aihara T.
    Breast Cancer Res Treat; 2011 May; 127(1):143-52. PubMed ID: 21347648
    [Abstract] [Full Text] [Related]

  • 3. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
    Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialistsa9 Group.
    Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 6. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y.
    Oncology; 2010 Aug; 79(5-6):376-81. PubMed ID: 21430407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A.
    J Clin Oncol; 2004 Nov 01; 22(21):4261-71. PubMed ID: 15514369
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S.
    Lancet Oncol; 2012 Apr 01; 13(4):345-52. PubMed ID: 22265697
    [Abstract] [Full Text] [Related]

  • 10. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.
    Cancer; 2004 Oct 01; 101(7):1482-9. PubMed ID: 15378476
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.
    Lancet; 2016 Feb 27; 387(10021):857-65. PubMed ID: 26686960
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB.
    Am J Health Syst Pharm; 2005 Feb 01; 62(3):266-73. PubMed ID: 15719584
    [Abstract] [Full Text] [Related]

  • 16. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 17. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P, Frassoldati A.
    Breast J; 2007 Nov 01; 13(1):28-35. PubMed ID: 17214790
    [Abstract] [Full Text] [Related]

  • 18. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
    Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB.
    Acta Oncol; 2009 Nov 01; 48(1):76-85. PubMed ID: 18777410
    [Abstract] [Full Text] [Related]

  • 19. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E.
    J Clin Oncol; 2006 Feb 20; 24(6):910-7. PubMed ID: 16484701
    [Abstract] [Full Text] [Related]

  • 20. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT.
    Cancer; 2006 May 15; 106(10):2095-103. PubMed ID: 16598749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.